ASCO 2017: Highlights from ASCO 2017 in Prostate Cancer

Speaker: Karim Fizazi

Karim Fizazi discusses the key results presented on prostate cancer about the use of abiraterone in newly diagnosed high risk metastatic hormone-naive setting, a study of continued active drug post PSA progression and some interesting data about biomarkers research in prostate cancer.

Karim Fizazi discusses the key results presented on prostate cancer about the use of abiraterone in newly diagnosed high risk metastatic hormone-naive setting, a study of continued active drug post PSA progression and some interesting data about biomarkers research in prostate cancer.

Abstracts as referenced in the ASCO 2017 programme

  • LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
  • LBA5003: Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).
  • 5004: A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific Antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
  • 5005: Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).